Learn about KISQALI, a treatment option for HER+, HER2- early breast cancer (eBC) and metastatic breast cancer (mBC). See full Prescribing and Safety Info.
People also ask
What is Kisqali Femara used for?
Kisqali Femara Co-Pack (ribociclib and letrozole) is commonly used for treating breast cancer that is hormone receptor-positive (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative and is advanced or has spread to other parts of the body (metastatic).
What is the life expectancy of Kisqali patients?
In one study, median OS at an 80-month check-in was 63.9 months with KISQALI + an AI vs 51.4 months with placebo + an AI.
What does Kisqali do to your body?
KISQALI is a targeted treatment for HR+ (ER+ and/or PR+), HER2- metastatic breast cancer that blocks, or interferes with, substances that play a key role in cancer cell growth and survival. KISQALI affects cancer cells, but can also affect healthy cells.
Is Kisqali a chemo drug?
Kisqali is a targeted therapy medication, not chemotherapy. It specifically targets CDK 4/6 proteins in cancer cells. Common Kisqali side effects include nausea, fatigue, and infection. Rare but serious side effects have been reported with Kisqali, too.
Taking KISQALI + hormone therapy · 600 mg (three 200-mg pills) orally, once a day · With or without food · 3 weeks on, followed by 1 week off ...
KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: • an aromatase ...
Kisqali - As bulas disponibilizadas neste portal destinam-se unicamente à consulta e referem-se às versões aprovadas junto à ANVISA.
7 days ago · Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes Kisqali side effects, interactions and ...
Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced ...
Kisqali (ribociclib) is a CDK4/6 inhibitor used to treat certain cases of estrogen-receptor-positive, HER2-negative breast cancer.
Learn about HR+, HER2- metastatic breast cancer treatment in premenopausal and postmenopausal women with KISQALI. See full Prescribing & Safety Info.
KISQALI is given as 600 mg (3 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) with either1: An AI once daily (continuously); in men and ...
The recommended dose of KISQALI is 600 mg (three 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off treatment ...
